Your browser doesn't support javascript.
loading
A Study on Pharmacokinetics of Bosentan with Systems Modeling, Part 2: Prospectively Predicting Systemic and Liver Exposure in Healthy Subjects.
Li, Rui; Kimoto, Emi; Niosi, Mark; Tess, David A; Lin, Jian; Tremaine, Larry M; Di, Li.
Afiliación
  • Li R; Systems Modeling and Simulation, Medicine Design, Pfizer Worldwide R&D, Cambridge, Massachusetts (R.L.); and Pharmacokinetics, Dynamics, and Metabolism, Medicine Design, Pfizer Worldwide R&D, Groton, Connecticut (E.K., M.N., D.A.T., J.L., L.M.T., L.D.) rui.li5@pfizer.com.
  • Kimoto E; Systems Modeling and Simulation, Medicine Design, Pfizer Worldwide R&D, Cambridge, Massachusetts (R.L.); and Pharmacokinetics, Dynamics, and Metabolism, Medicine Design, Pfizer Worldwide R&D, Groton, Connecticut (E.K., M.N., D.A.T., J.L., L.M.T., L.D.).
  • Niosi M; Systems Modeling and Simulation, Medicine Design, Pfizer Worldwide R&D, Cambridge, Massachusetts (R.L.); and Pharmacokinetics, Dynamics, and Metabolism, Medicine Design, Pfizer Worldwide R&D, Groton, Connecticut (E.K., M.N., D.A.T., J.L., L.M.T., L.D.).
  • Tess DA; Systems Modeling and Simulation, Medicine Design, Pfizer Worldwide R&D, Cambridge, Massachusetts (R.L.); and Pharmacokinetics, Dynamics, and Metabolism, Medicine Design, Pfizer Worldwide R&D, Groton, Connecticut (E.K., M.N., D.A.T., J.L., L.M.T., L.D.).
  • Lin J; Systems Modeling and Simulation, Medicine Design, Pfizer Worldwide R&D, Cambridge, Massachusetts (R.L.); and Pharmacokinetics, Dynamics, and Metabolism, Medicine Design, Pfizer Worldwide R&D, Groton, Connecticut (E.K., M.N., D.A.T., J.L., L.M.T., L.D.).
  • Tremaine LM; Systems Modeling and Simulation, Medicine Design, Pfizer Worldwide R&D, Cambridge, Massachusetts (R.L.); and Pharmacokinetics, Dynamics, and Metabolism, Medicine Design, Pfizer Worldwide R&D, Groton, Connecticut (E.K., M.N., D.A.T., J.L., L.M.T., L.D.).
  • Di L; Systems Modeling and Simulation, Medicine Design, Pfizer Worldwide R&D, Cambridge, Massachusetts (R.L.); and Pharmacokinetics, Dynamics, and Metabolism, Medicine Design, Pfizer Worldwide R&D, Groton, Connecticut (E.K., M.N., D.A.T., J.L., L.M.T., L.D.).
Drug Metab Dispos ; 46(4): 357-366, 2018 04.
Article en En | MEDLINE | ID: mdl-29330219
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Sulfonamidas / Hígado Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Animals / Humans Idioma: En Revista: Drug Metab Dispos Asunto de la revista: FARMACOLOGIA Año: 2018 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Sulfonamidas / Hígado Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Animals / Humans Idioma: En Revista: Drug Metab Dispos Asunto de la revista: FARMACOLOGIA Año: 2018 Tipo del documento: Article